Arcus (RCUS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Image source: The Motley Fool. DATE Wednesday, Feb. 25, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Terry J. Rosen President — Juan C. Jaen Chief Financial Officer — Robert Goeltz Chief Operating Officer — Jennifer Jarrett Chief Medical Officer — Richard Marcus Need a quote from a Motley Fool analyst? Email pr@fool.com Full Conference Call Transcript our CEO, Terry Rosen, to begin. Terry Rosen: Thanks very much, Holly, and thank you, everyone, for joining us this afternoon. 2026 is going to be a transformative year for Arcus Biosciences, Inc. As you know, we have been focused on establishing casdatifan as the unequivocal best-in-class HIF2a inhibitor and the new standard of care for clear cell renal cell carcinoma. This year is going to be another substantial year for data presentations, as well as the advancement and expansion of our Phase 3 clinical program for casdatifan. I want to emphasize, particularly to those who are new to Arcus B
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences to Participate in Two Upcoming Investor ConferencesBusiness Wire
- Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire
- Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney CancerBusiness Wire
RCUS
Earnings
- 2/25/26 - Beat
RCUS
Sec Filings
- 2/25/26 - Form S-3ASR
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- RCUS's page on the SEC website